Articles from Edison Investment Research Limited

LONDON, UK / ACCESSWIRE / June 7, 2022 / This note focuses on the outlook for income-driven returns from Regional REIT (RGL). With the ‘return to the office' accelerating, RGL expects a positive demand-supply balance to generate rental growth, increased occupancy and valuation gains. Q122 DPS increased c 3% to 1.65p. Income risk is mitigated by portfolio diversification, while fully fixed or hedged borrowing costs protect against further interest rate increases.

LONDON, UK / ACCESSWIRE / June 1, 2022 / InMed Pharmaceuticals has reported fiscal Q322 results (ending 31 March) benefiting from commercial sales into the health and wellness market. Its product launches of high-value rare cannabinoids contributed to its $0.3m revenues and should provide most sales in the near future. It has also made progress with its pharmaceutical drug development program for treating glaucoma, where it completed the FDA pre-investigational new drug (pIND) meeting for candidate INM-088. We continue to see InMed offering near-term revenue generation combined with the longer-term value of its pharma drug development programs.

LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address a complex and untapped segment, childhood brain cancer. Due to the challenges in addressing this unmet need, including significant hurdles in enrolling patients for a clinical trial, there is a vacuum of options for those served with this diagnosis. As Kazia is working to pioneer this sub-segment, leveraging its network, in this note we examine the science and attempt to connect the dots on the potential market opportunity and dynamics despite the limited data points to date.

LONDON, UK / ACCESSWIRE / May 25, 2022 / Canacol's recent independent prospective resources audit has assigned 7.6tcf to the company's Lower and Middle Magdalena Valley (LMV and MMV) assets, up from 1.7tcf in 2021 and with 6.6tcf sitting in the untapped MMV. This will be key to the company's success as it looks beyond its core LMV producing area to secure its targeted reserves replacement ratio of 200% per year (on average). The company's first test of the MMV will be the Pola-1 well spudding in Q322, targeting 470bcf of mean gross risked prospective resources. Success here would be transformational given that Canacol currently holds 607bcf of 2P reserves. We believe the share price does not reflect the exploration upside and value the company at C$6.29/share, more than double the current share price.

LONDON, UK / ACCESSWIRE / May 24, 2022 / Braemar recently completed a corporate transformation that will see it move away from being a widely spread shipping services company, to grow into a clearly focused shipbroking operation. Allied to the transformation is the company's growth strategy, supported by growing global trade, and shipping's status as the most energy-efficient and lowest carbon method of freight transport, that has management focused on doubling the business inside four years. We value the shares at 400p, a c 40% premium to the current price, but see greater upside as evidence of success is delivered over the next two to three years.

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

LONDON, UK / ACCESSWIRE / April 13, 2022 / Pan American Silver (PAAS) is one of the world largest primary silver producers, with key operations in the Americas. While the well-timed acquisition of Tahoe Resources in 2019 boosted exposure to gold, given the quality and the calibre of its key silver assets, PAAS remains predominantly a silver play. Although the COVID-19 pandemic and current geopolitical tensions have supported investment demand and

LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential regulatory filing, if data are positive. Recent C-suite appointments in the United States suggest an increased focus on commercialization, particularly in the US market. Second asset EVT801 has progressed to human studies, with the first patient enrolled

LONDON, UK / ACCESSWIRE / March 18, 2022 / Since we published our last outlook note on KEFI in July 2021, the company has raised additional equity to deleverage its balance sheet and announced a turnaround in the working environment in Ethiopia, plus the take-off of its projects in Saudi Arabia. In particular, KEFI reports the civil war in Ethiopia effectively ceased in December with no clashes outside the northern part of the country (which is

LONDON, UK / ACCESSWIRE / March 15, 2022 / MeaTech 3D (MeaTech) is developing proprietary three-dimensional printing technology to be used in conjunction with its cultured meat process, which will enable the manufacture of premium meat products such as marbled steak. Alternative meat demand is booming and cellular agriculture could represent a new solution to the ever-increasing demand for protein. Cellular meat has the potential to significantly

LONDON, UK / ACCESSWIRE / March 14, 2022 / FY21 ended on a firm note, modestly exceeding expectations. Price inflation will come through in a strong revenue performance but also some temporary margin dilution. As a result, the benefits of having repositioned and strengthened the group in recent years may not be visible to investors at first. We believe Epwin is well placed to regain and exceed historic levels of profitability as industry pricing

LONDON, UK / ACCESSWIRE / February 17, 2022 / 1Spatial (SPA) announced a three-year contract worth c $0.8m with the State of Montana for its Next Generation 911 solution. The Montana contract, along with recent large contract wins, the accelerating pace of new business, the transition to a higher-margin SaaS business, increased collaboration among data users and success with the ‘Land and Expand' strategy should support a c 6% CAGR through

LONDON, UK / ACCESSWIRE / February 16, 2022 / InMed Pharmaceuticals' (INM's) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the health and wellness market, with revenues of $0.3m, all cannabichromene (CBC). As of January, it also began selling cannabicitran (CBT) to the health and wellness market. The now-completed BayMedica acquisition boosts its product portfolio for rare cannabinoids

LONDON, UK / ACCESSWIRE / February 10, 2022 / Oryzon is making progress with its two epigenetic drugs, iadademstat for oncology and vafidemstat for CNS indications (both are lysine-specific demethylase 1A, or LSD1, inhibitors). The company's R&D strategy has been to select indications where there is a scientific rationale for intervention with an epigenetic therapy and then conduct quick and relatively small trials, but with patient sample

LONDON, UK / ACCESSWIRE / February 7, 2022 / Technicolor is on track to meet FY21 and FY22 management guidance (maintained at the Q3 results in November) on EBITDA and EBITA, despite supply constraints resulting from the pandemic, and our forecasts for these were unchanged. Demand in both Technicolor Creative Studios (TCS) and Connected Home remains robust, with financial performance constrained in the former by industry talent shortages and in

LONDON, UK / ACCESSWIRE / December 21, 2021 / Studio Retail Group (SRG) is a focused play on the growth of online value non-food retail. Management's aspiration to accelerate medium-term revenue growth, to a CAGR of 10-15% over four to six years, is expected from gains in active credit customer numbers and spend per customer. SRG's valuation is at a significant discount to its own historical multiples (despite an improved medium-term growth

LONDON, UK / ACCESSWIRE / November 17, 2021 / With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its commercial stage as BayMedica has been selling cannabichromene (CBC) in bulk. InMed has also advanced past the healthy volunteer stage in the INM-755 clinical program through the initiation of the INM-755 Phase II trial (755-201-EB) in up to 20

LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients, as well as initial data for paxalisib in the treatment of brain metastases (BMs). Additionally, the Phase I for EVT801 is expected to begin enrolment by year-end. We have increased our valuation to

LONDON, UK / ACCESSWIRE / October 11, 2021 / ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted with five patients left to treat. Two patients are scheduled for treatment in October. The company expects to report some data by March 2022, which could potentially open the way to a crucial partnering deal. Full efficacy data at six months

LONDON, UK / ACCESSWIRE / October 6, 2021 / Prima, a potentially breakthrough wireless bionic vision system (BVS) that generates electrical impulses at the retinal level, continues to advance through the PRIMAvera pivotal EU study. Prima aims to restore a form of central visual perception in patients with advanced dry age-related macular degeneration (dry-AMD) involving geographic atrophy (GA). While we have pushed back our potential launch

LONDON, UK / ACCESSWIRE / September 28, 2021 / Carmat recently announced that it has implanted nine of its physiologic heart replacement therapies (PHRT) since July, six of which were commercial implants (under the brand name Aeson in the EU) while three were part of the early feasibility study (EFS) in the United States. These nine implants are associated with approximately €2m in product revenue, which will be booked in H221. Importantly,

LONDON, UK / ACCESSWIRE / September 20, 2021 / InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the manufacture and commercialization of rare cannabinoids. This is an all-stock transaction in which InMed will issue 1.78m shares to BayMedica's equity and convertible debt holders. At the current stock price, this values BayMedica at approximately US$4m.

LONDON, UK / ACCESSWIRE / July 13, 2021 / Phase IIb data from the QUORUM study in heart failure (HF) patients will be presented at the European Society of Cardiology meeting, which will be held virtually from 27-30 August. If positive, we believe this data may be truly transformational for the company and we would expect partnership discussions to intensify with some of the global players in the cardiovascular space. We maintain our valuation of

LONDON, UK / ACCESSWIRE / July 7, 2021 / After a period of uncertainty, the peaceable conclusion of the recent general election in Ethiopia should provide KEFI with the opportunity to fund Tulu Kapi in an environment in which the Ethiopian government is keen to both encourage investment and generate tax and export earnings. Since our last note on the company, we have updated our project timings, costings and funding assumptions to come up with a

LONDON, UK / ACCESSWIRE / May 28, 2021 / Oxford Biomedica (OXB) is one of few global lentiviral vector manufacturers with capacity in a thriving cell and gene therapy industry, and its FY20 results highlight strong operational progress throughout the business. OXB boasts a diversified revenue base; and FY20 benefited from new deals including Juno/BMS covering multiple CAR-T programmes, as well as increased bioprocessing and commercial development

LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for €1m upfront, €308m in milestones and tiered single-digit royalties. EVT801 was developed as part of a collaboration between Evotec and Sanofi. Kazia will be responsible for development, but will collaborate with and have access to Evotec

LONDON, UK / ACCESSWIRE / April 13, 2021 / While Regional REIT's (RGL's) uninterrupted quarterly FY20 DPS payments backed by consistently strong rent collection has been known for some time, the recent FY20 results confirmed full cover by EPRA earnings. RGL remains very positive about the prospects for high-quality regional offices with affordable rents and with its diversified portfolio of attractively yielding assets RGL will continue